anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a preparation containing an effective amount of a stabilized polyol and a sufficient amount of a buffering agent to maintain the pH level within a specific range, with physical stability, chemical stability and biological activity maintained, and capable of controlledly releasing somatotropin over a long period. CONSTITUTION: This somatotropin preparation contains (A) >=10 (pref. >=20)wt.% of biologically active somatotropin, (B) an effective amount (20-80wt.%) of a polyol such as glycerol or tris(hydroxymethyl)aminomethane, and (C) a sufficient amount of a buffering agent (e.g. histidine hydrochloride, alkali metal phosphate) to attain the pH level so as to maintain the biological activity of the somatotropin over a sufficiently long period (namely, between 4.5 and a greater value, either 7 or the isoelectric point of the somatotropin). It is preferable that a wetting agent such as a nonionic surfactant (e.g. a polyethoxylated sorbitan ester) is added in preparing this preparation.
The present invention provides a nanometre titanium dioxide anti— tumor drug with PTT/SDT effect and relates to the field of biological pharmaceutical. The nanometre titanium. dioxide anti— tumor drug with PTT/SDT effect includes the following steps: Sl 5 heating treatment, Ti02 sample and Al were respectively heated in a two—zone tube furnace; SZ annealing treatment, Al—TiOZ—X was put into the annealing furnace,and the samples anneal for 12h by seguentially passing argon gas at 800°C and 900°C into the furnace.; S3 surface decoration treatment, the surface of Ti02—x 10 NPS was decorated with the glut—amine; S4 centrifuge treatment,the centrifuge machine centrifuged the composition to obtain TiOZ—X@GL NPS. Through the synthesis of TiOZ-X@GL NPS based on the "sugar— coated bullets" theory, and targeting the delivery TiOZNPs enters into tumor tissues through active uptake of glut—amine by tumor 15 cells, so as to achieve the purpose of killing or inhibiting tumor cells. (+ Fig. l)
A female, term neonate, born via vaginal delivery to a G5P1D1A3 hypothyroid mother with a history of an elder sibling being homozygous for HSD17B4 mutation, diagnosed while working up his progressive neurological disorder and succumbing to the same. The family screening revealed that both parents were heterozygous carriers of the same mutation in the gene HSD17B4 After genetic counselling, amniocentesis revealed the fetus to be having homozygosity for the same mutation. In view of precious pregnancy, normal antenatal scans and investigations, the pregnancy was continued, and baby was born with a birth weight of 2.65 kg and had a smooth perinatal transition. Parents were counselled regarding the course of the illness, possible complications and the need for regular follow-up. Ultrasound of the abdomen, pelvis and head was normal in the neonatal period. She was vaccinated as per the national schedule and gaining weight normally.
Patients receive acalabrutinib PO BID on days 1-28. Patients also receive venetoclax PO QD on days 1-28 days of cycles 13-18. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
FLUORESCITE® Injection 10% is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. Rare cases of death due to anaphylaxis have been reported. [see Warnings and Precautions (5.1) and Adverse Reactions (6)].

Fluorescein sodium can induce serious intolerance reactions. These reactions of intolerance are always unpredictable but they are more frequent in patients who have previously experienced an adverse reaction after fluorescein injection (symptoms other than nausea and vomiting) or in patients with history of allergy such as food or drug induced urticaria, asthma, eczema, allergic rhinitis.

Detailed questioning of each patient is recommended before the angiography to evaluate any prior history of allergy.
HBV RNA destabilizers are a class of small-molecule compounds that target the noncanonical poly(A) RNA polymerases PAPD5 and PAPD7, resulting in HBV RNA degradation and the suppression of viral proteins including the hepatitis B surface antigen (HBsAg). AB-161 is a next-generation HBV RNA destabilizer with potent antiviral activity, inhibiting HBsAg expressed from cccDNA and integrated HBV DNA in HBV cell-based models. AB-161 exhibits broad HBV genotype coverage, maintains activity against variants resistant to nucleoside analogs, and shows additive effects on HBV replication when combined with other classes of HBV inhibitors. In AAV-HBV-transduced mice, the dose-dependent reduction of HBsAg correlated with concentrations of AB-161 in the liver reaching above its effective concentration mediating 90% inhibition (EC90), compared to concentrations in plasma which were substantially below its EC90, indicating that high liver exposure drives antiviral activities. In preclinical 13-week safety studies, minor non-adverse delays in sensory nerve conductance velocity were noted in the high-dose groups in rats and dogs. However, all nerve conduction metrics remained within physiologically normal ranges, with no neurobehavioral or histopathological findings. Despite the improved neurotoxicity profile, microscopic findings associated with male reproductive toxicity were detected in dogs, which subsequently led to the discontinuation of AB-161's clinical development.
All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
The invention provides a traditional Chinese medicine food therapy formula for well treating hyperosteogeny. According to the traditional Chinese medicine food therapy formula, raw materials are easy to obtain, the traditional Chinese medicine food therapy formula is easy to make and convenient to use. The traditional Chinese medicine food therapy formula is prepared from rhizoma drynariae, radix astragali, radix angelica sinensis, ligusticum wallichii, cloves, cinnamon, angelica dahurica, villous amomum fruits, Pseudo-ginseng, licorice roots, fresh ginger and bone silky fowl and is prepared through the following steps of decocting liquid medicines twice, filtering the liquid medicines for standby application, selecting one bone silky fowl, removing feathers and internal organs, thoroughly cleaning the bone silky fowl without the feathers and the internal organs, placing the processed bone silky fowl in a marmite, adding the liquid medicines, and performing stewing until chicken meat is separated from bones and mashed. People can eat the chicken meat and drink soup, for 2-3 times every day, and each dose of the traditional Chinese medicine food therapy formula is taken within two days. The traditional Chinese medicine food therapy formula disclosed by the invention has the treatment effects that after 2-8 doses are used, pains can be alleviated even treated, joint functions return to normal, and through X-ray film examination, hyperplasia is obviously alleviated. The traditional Chinese medicine food therapy formula has an obvious treatment effect on symptoms of yin asthenia generating intrinsic heat, tidal fever, night sweating, sultriness of the palms and soles and the like.
PURPOSE: An emulsified hydrogel composition is provided to contain moisture and oil in skin, to ensure high content of skin active ingredients dissolved in an oil phase, and to improve function. CONSTITUTION: An emulsified hydrogel composition contains an emulsion containing 45-60 wt% of an aqueous phase and 145-30 wt% of an oil phase, and 20-30 wt% of a gelling solution. The aqueous phase contains 1-20 wt% of a moisturizer, 78-98 wt% of purified water, and 0.1-3 wt% of an additive. The oil phase contains 15-25 wt% of an emulsifier, 60-85 wt% of a skin softening agent, and 0.1-15 wt% of a skin conditioning agent. The gelling solution contains 0.1-20 wt% of a gelling polymer and 80-95 wt% of polyvalent alcohol. A method for preparing the emulsified hydrogel composition comprises: a step of heating 45-60 wt% of the aqueous phase and 15-30 wt% of the oil phase at 70-80 deg. C; a step of mixing the oil phase and the aqueous phase at 70-80 deg. C and preparing an emulsion; and a step of adding 20-30 wt% of the gelling solution to the emulsion, mixing at 70-80 deg. C, and stirring every 20-40 minutes.
Immunosuppressive tumor microenvironment (TME) contributes to tumor progression and causes major obstacles for cancer therapy. Phosphoglycerate mutase 1 (PGAM1) is a key enzyme involved in cancer metabolism while its role in remodeling TME remains unclear. In this study, we reported that PGAM1 suppression in breast cancer (BC) cells led to a decrease in M2 polarization, migration, and interleukin-10 (IL-10) production of macrophages. PGAM1 regulation on CCL2 expression was essential to macrophage recruitment, which further mediated by activating JAK-STAT pathway. Additionally, the CCL2/CCR2 axis was observed to participate in PGAM1-mediated immunosuppression via regulating PD-1 expression in macrophages. Combined targeting of PGAM1 and the CCL2/CCR2 axis led to a reduction in tumor growth in vivo. Furthermore, clinical validation in BC tissues indicated a positive correlation between PGAM1, CCL2 and macrophage infiltration. Our study provides novel insights into the induction of immunosuppressive TME by PGAM1 and propose a new strategy for combination therapies targeting PGAM1 and macrophages in BC.
Vagifem 10 mcg (estradiol vaginal inserts) are small, white, film-coated inserts containing 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. Each insert of Vagifem 10 mcg contains the following excipients: hypromellose, lactose monohydrate, maize starch and magnesium stearate. The film coating contains hypromellose and polyethylene glycol. Each Vagifem insert is 6 mm in diameter and is placed in a disposable applicator. Each insert-filled applicator is packaged separately in a blister pack. Vagifem inserts are used intravaginally. When the insert comes in contact with the vaginal mucosa, estradiol is released into the vagina.

Estradiol hemihydrate is a white, almost white or colorless crystalline solid, chemically described as estra-1,3,5 (10)-triene-3,17β-diol. The chemical formula is C18H24O2 • ½ H2O with a molecular weight of 281.4.

The structural formula is:
Indirect respiratory quotient (RQ) measurement involves indirect calorimetry, which measures O2 and CO2 inspired and expired fractions. This measurement is usually used to estimate energy expenditure and which energetic substrate is preferentially used in resuscitation patients. Litterature demonstrated in a mouse model that the formation of hemorrhagic shock was associated with a change in RQ due to VCO2 and VO2 imbalance. RQ was able to distinguish anaerobic metabolism and corrected itself with correction of shock. Recently in Litterature showed a link between lactate production, cardiac output and the evolution of the RQ measured by indirect calorimetry in a resuscitation patient. Also, these authors raise the question of a possible use of the RQ in intensive care as an early non-invasive marker of anaerobic metabolism that can replace the invasive ones usually used (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2). However, the measurement of inspired and expired fractions in O2 and CO2 is part of the systematic monitoring of the intubated-ventilated patient in the operating room. The measurement of the VO2, VCO2 and the RQ could therefore be done from these fractions inspired and expired in O2 and CO2 by the following equation:

RQ = (FeCO2-FiCO2) / (FiO2-FeO2) The main objective of our work is to demonstrate the ability of the RQ, measured indirectly from the anesthesia ventilator, to predict the occurrence of anaerobic metabolism in patients operated of major non-cardiac surgical operation in the operating room. Secondly, the objective is to evaluate the association between the variations of the RQ, EtCO2, Dc, ScVO2, venoarterial PCO2 gradient, venoarterial PCO2 gradient/arteriovenous O2 content difference and lactate levels at different times during the surgical procedure and depending on the occurrence of postoperative complications.
The pharmaceutical combined contraceptive agent contains two hormonal components packed in the common unit but in the different compartments and intended for the consecutive oral use. The specified number of daily dose units comprising the set may be taken out separately. The first component consists of estrogen and gestagen at a dose sufficient for inhibiting ovulation in one-phase or multi-phase mode. The second component contains only estrogen as a biologically active hormonal substance. The first hormonal component covers 24 daily dosage units, while the second one covers 4-10 daily dosage units. The daily dosage units of the first hormonal component do not contain the combination of the biogenic estrogen and the synthetic estrogen. The total number of the daily dosage units of the hormones equals the total number of the days in the desired cycle.
Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
A computer-implemented method and a computer system for identifying a phylogenetic tree from a plurality of biological sequences is provided. Each biological sequence is associated with a sampling date. First, the plurality of biological sequences is aligned and a distance matrix is obtained. Then, a subset of these sequences without any duplicated sequences is selected and a directed graph representation of the subset of biological sequences is generated based the associated sampling dates. Then, a minimum spanning tree is computed from the weighted directed graph representation. Then, in an iterative procedure, the sequences of unsampled evolutionary intermediates are inferred from mutation patterns that reflect the difference in sequence between the nodes in the minimum spanning tree. The new sequences are added with associated time stamps to the sequence set. Then, sets of identical sequences are removed. Then, an optimum branching is recomputed. This step is repeated until no new intermediates are found. In the final step, the sequences that have been set aside in the initializing step are added to the plurality of sequences derived in the update step. From this plurality of sequences an optimum branching is computed and identified as the phylogenetic tree. Amino acid changes repeatedly occurring on the internal branches of the obtained tree can be used to identify sequences and associated viral isolates suitable as vaccine strains for the following influenza season.
A case control study conducted on 120 women coming to Cairo University Maternity Hospital .Patients who meet the inclusion criteria were asked to participate in the study and a verbal consent was obtained from each patient. Patients will be divided into three equal groups (A, B, C). A single dose of the drug (placebo or HBB 20mg or HBB 40 mg) will be injected intravenously slowly to groups A, B, C respectively. Labouring mothers will be monitored in bed. Vaginal examination will be conducted every two hours. The duration of the first stage was calculated from the time of cervical dilatation of three to four centimeters in active labour until a fully dilated cervix will be observed
This is a prospective randomized pilot clinical trial, stratified by primary tumor site, to evaluate the degree of xerostomia and quality of life (QOL) in subjects with HN-SQCC treated with radiation therapy under margin-based and robust radiotherapy treatment plans. Margin-based plans will use both biological (biological optimization) and physical objectives whereas robust planning will use physical objectives for sparing of the parotid glands. Intensity-modulated radiation therapy (IMRT) and standard chemotherapy will be used. QOL (quality of life) will be measured using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 questionnaire and EORTC QLQ-H\&N35 (head and neck) module before radiotherapy (baseline) and then 3, 6, 9 and 12 months after radiotherapy. Xerostomia will be measured in study subjects using two patient-reported scoring systems completed by each subject before radiotherapy and then 3, 6, 9, and 12 months after radiotherapy: Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) LENT/SOMA grading system and the University of Michigan's Xerostomia Questionnaire (XQ). The data collected by this randomized pilot clinical trial will be used to inform the design of, and decision-making for, future larger studies that seek to compare different methods of radiotherapy planning in the treatment of HN-SQCC.
Provided is a system of integrating blood drawing serial numbers and examination information for an examination branch, which comprises an examination information unit, a number calling management unit, a number taking unit, a ticket printer, and an electronic information billboard. The examination information unit has a central server for organizing and distributing the blood drawing sequence. The number calling management unit performs a number calling service operation according to the number of persons under blood drawing and the examination categories transmitted from the central server. The number taking unit sends out a request based on the aforementioned examination categories, and the central server gives a blood drawing serial number. The ticket printer is provided to print a blood drawing serial number ticket of the person under blood drawing. After the person under blood drawing has obtained the blood drawing serial number ticket, the blood drawing serial number of the person under blood drawing is displayed on the electronic information billboard, so that the person under blood drawing realizes to which examination counter he/she should go for performing blood drawing and sampling operation.
Participants of the verum group take Bryophyllum 50% chewable tablets starting the day after study inclusion. Participants take 2 tablets, four times a day for 2 weeks. If the birth takes place before the end of the 2 weeks, the study participation is terminated early.
FIELD: medicine, homeopathy, ophthalmology. SUBSTANCE: agent has Mercurius corrosivus, Belladonna, Apis, Silicea taken in equal ratios in the dilution C3. Conium can be added to homeopathic agent if necessary. Proposed agent ensures to arrest acute inflammation for some hours, rapid and effective treatment of keratitis of different forms in patients of all age groups. Invention can be used for treatment of patients with keratitis of different etiology (traumatic, viral, bacterial and so on). EFFECT: enhanced effectiveness of agent. 3 cl, 2 ex
FIELD: medicine, cosmetics. SUBSTANCE: invention relates to cosmetic agents for face skin care. Cream has an oily phase as olive, sunflower or perfume oil, structure-forming components, vitamin E as a biologically active addition, paraform, para-hydroxybenzoic acid propyl ester as preserving agents, perfume composition and water. Cream has additionally allantoin, fruit concentrate and cotton, salad or fruit kernels and almond nuts oil, vaseline oil, distilled monoglycerides, cetyl alcohol, emulsifying agent, propylene glycol, rectified ethyl alcohol, bronitrol or bronopol, para-hydroxybenzoic acid methyl ester. Components are taken in the definite quantitative ratios. Cream can be applied easily, it shows quick absorption, softening effect, cleanses skin from keratinized cells and does not remain fat brilliance. EFFECT: improved quality and properties of cream. 1 cl, 2 tbl
TB continues to be a major global health problem, with an estimated 9.4 million new cases and 1.3 million deaths from TB in 2009. Effective treatment is available, but the current standard therapy consists of 4 different drugs that must be given for 6 months to be effective. RPT is a rifamycin antibiotic approved by the Food and Drug Administration (FDA) to be given twice weekly during the intensive phase of TB treatment and once weekly during the continuation phase of TB treatment. However, studies using this regimen have seen high relapse rates of TB; use of higher and/or more frequent doses may be necessary to attain higher cure rates. This study will evaluate 2 strategies for optimizing RPT exposure: dividing the daily dose in order to increase absorption/overall drug exposure and providing the dose together with food.

Participants will be randomly assigned to one of 4 arms: Arm 1A, Arm 1B, Arm 2A, or Arm 2B. The first 12 participants who indicate that they are willing to remain on the study for up to 12 weeks will be assigned to Arm 2A; all others will be randomized to Arm 1A, 1B, or 2B. Participants in all arms will receive daily RPT from Day 1 to 14, followed by a washout period from Day 15 to 42 during which no RPT will be given, followed by a second period of daily RPT from Day 43 to 56 (and continuing through Day 70 for participants in Arm 2A). Arms 1A and 2B will evaluate twice-daily versus once-daily RPT taken with low-fat meals; Arms 2A and 2B will evaluate once-daily RPT given with an egg versus with a low-fat breakfast.

Total study duration will range from 63 to 70 days for Arms 1A, 1B, and 2B, with 10 study visits: 4 intensive pharmacokinetic (PK) sampling visits (at Days 0 to 2, 13 to 15, 42 to 44, and 55 to 57) and 6 other visits at screening and Days 7, 21, 35, and 49, with the final visit between Days 63 and 70. Total study duration for Arm 2A will range from 77 to 84 days, with 12 study visits: 5 intensive PK sampling visits (over Days 0 to 2, 13 to 15, 42 to 44, 55 to 57, and 69 to 71) and 7 other visits at screening and Days 7, 21, 35, 49, and 64, with the final visit between Days 77 and 84. Intensive PK visits will require the participant to be admitted to the clinic for 1 or 2 nights and to have blood collected multiple times. Interim study visits may consist of giving a medical history, undergoing a physical exam and blood collection, and undergoing a pregnancy test for women of reproductive potential. Participants also will be required to keep a diary of the times they took outpatient study drugs, any medications taken other than the study drug, and any symptoms experienced.
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.